Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 4/20 | 0.53 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18502080 | 0.97 | HTR1A (0.52) | MBTD1L3MBTL1HTR7SFRP1KDM4E | |
| SCHEMBL18501758 | 0.90 | L3MBTL1 (0.54) | MBTD1L3MBTL1HTR7KDM4EGAA | |
| SCHEMBL18502084 | 0.90 | KMT2A (0.60) | MBTD1L3MBTL1HTR7KDM4EGAA | |
| SCHEMBL17194302 | 0.90 | L3MBTL1 (0.70) | MBTD1L3MBTL1HTR7KDM4EGAA | |
| SCHEMBL18506938 | 0.88 | L3MBTL1 (0.52) | MBTD1L3MBTL1HTR7SFRP1KDM4E | |
| SCHEMBL18502057 | 0.88 | MBTD1 (0.52) | MBTD1L3MBTL1HTR7SFRP1LMNA | |
| SCHEMBL17194300 | 0.87 | HTR7 (0.61) | MBTD1L3MBTL1HTR7HTR1AKMT2A | |
| SCHEMBL18507066 | 0.87 | HTR7 (0.53) | MBTD1L3MBTL1HTR7KDM4EGAA | |
| SCHEMBL18502078 | 0.87 | L3MBTL1 (0.65) | MBTD1L3MBTL1HTR7KDM4EGAA | |
| SCHEMBL17194235 | 0.86 | SIGMAR1 (0.65) | MBTD1L3MBTL1HTR7GAASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809602-B2 | Compounds for treating viral infections | INSTITUT PASTEUR KOREA (KR) | 2017-11-07 | — | — | US | disclosed |
| US-9809602-B2 | Compounds for treating viral infections | INSTITUT PASTEUR KOREA (KR) | 2017-11-07 | — | — | US | disclosed |
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | INSTITUT PASTEUR KOREA (KR) | 2017-02-16 | — | — | US | disclosed |
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | INSTITUT PASTEUR KOREA (KR) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, EIF2AK2 | MBTD1 4074/4885L3MBTL1 992/4885HTR7 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.